RIVM European Reference Lab for vector-borne infections The European Commission (EC) has designated RIVM as the current European Reference Lab (EURL) for vector-borne viral pathogens.
Menno de Jong appointed director of RIVM Centre for Infectious Disease Control Starting 1 May 2024, Professor Menno de Jong will take on the role of director of RIVM’s Centre for Infectious Disease Control (CIb) . He succeeds Jaap van Dissel, who is retiring in April 2024.
Pneumonia increase likely caused by multiple viruses and bacteria More patients with pneumonia visited their GP from August 2023 on than in previous years. The rise in cases of pneumonia among children, adolescents and young adults aged 5–25 years is particularly notable.
Respiratory infections widespread, even more important to follow recommendations The number of people in the Netherlands with respiratory symptoms continues to increase. Besides COVID-19 and rhinovirus, the number of people who have flu is also increasing. We are also seeing more and more people with pneumonia. Some of these cases are caused by the bacteria Mycoplasma pneumoniae.
Respiratory infections now in season More and more people are coughing and sneezing, although it is not an epidemic at this point. The season in which respiratory infections circulate in the Netherlands has now started. There are various viruses that can cause respiratory infections.
Biosafety and Biosecurity on the Global Health Security Agenda Since 2018, the Netherlands leads the way in the field of "Biosafety and Biosecurity" within the international Global Health Security Agenda (GHSA).
Global Infectious Disease Control hampered by the CBD Nagoya Protocol So far, none of the models used by international networks of biobanks to arrange the legal responsibility under the CBD-Nagoya protocol works efficiently.
RIVM participates in large EU project to head up global fight against infectious diseases COMPARE, a large EU project intends to speed up the detection of, and response to disease outbreaks among humans and animals worldwide, through the use of new genome technology.